Table 1.
Anthropometric, endocrine, and metabolic parameters of the patients in treatment groups.
| Parameter M ± SD |
Yarina | Inofolic | Yarina + inofolic | |||
|---|---|---|---|---|---|---|
| Group I | Group II | Group III | ||||
| Baseline | After 3 months | Baseline | After 3 months | Baseline | After 3 months | |
| BMI kg/m2 | 22.74 ± 3.75 | 23.03 ± 3.6∗ | 22.3 ± 3.08 | 21.9 ± 2.5∗ | 22.24 ± 3.26 | 21.99 ± 2.57 |
| Weight kg | 61.1 ± 9.92 | 61.9 ± 9.47∗ | 58.6 ± 9.3 | 57.4 ± 7.6∗ | 58.95 ± 9.6 | 58.05 ± 7.6 |
| PRL ng/ml | 11.70 ± 5.11 | 12.01 ± 4.5 | 12.98 ± 5.75 | 12.5 ± 5.32 | 13.39 ± 4.5 | 13.03 ± 4.35 |
| LH IU/I | 10.42 ± 3.9 | 8.01 ± 2.9∗∗ | 9.11 ± 5.7 | 7.56 ± 4.5∗ | 13.1 ± 5.58 | 8.42 ± 3.7∗∗ |
| DHEA-S µg/ml | 2.03 ± 0.7 | 1.82 ± 0.46∗ | 2.09 ± 0.50 | 1.89 ± 0.59 | 2.3 ± 0.67 | 1.9 ± 0.38∗ |
| TT ng/ml | 0.72 ± 0.25 | 0.58 ± 0.57 | 0.73 ± 0.25 | 0.73 ± 0.46 | 0.70 ± 0.23 | 0.51 ± 0.16∗∗ |
| FT pg/ml | 4.26 ± 2.46 | 2.74 ± 1.16∗ | 3.82 ± 2.01 | 2.98 ± 0.94∗ | 3.42 ± 2.16 | 2.12 ± 0.8∗∗ |
| FAI | 7.13 ± 3.8 | 3.8 ± 2.6∗∗ | 6.7 ± 5.7 | 5.99 ± 5.24 | 8.1 ± 5.5 | 2.94 ± 1.04∗∗ |
| SHBG nmol/l | 45.03 ± 24.39 | 55.42 ± 25.7∗∗ | 53.7 ± 27.4 | 56.29 ± 24.3 | 47.4 ± 29.2 | 65.01 ± 22.5∗∗ |
| Glucose mmol/l | 4.61 ± 0.74 | 4.36 ± 0.53∗ | 4.64 ± 0.65 | 4.39 ± 0.56∗ | 4.64 ± 0.72 | 4.42 ± 0.52 |
| C-peptide ng/ml | 1.6 ± 0.7 | 1.53 ± 0.34 | 1.92 ± 0.7 | 1.82 ± 0.34∗ | 1.52 ± 0.7 | 1.22 ± 0.57∗ |
| Insulin µIU/ml | 8.07 ± 5.24 | 8.12 ± 4.3 | 8.5 ± 6.7 | 5.2 ± 3.04∗ | 8.67 ± 4.7 | 6.67 ± 2.79∗ |
| HOMA-IR | 1.59 ± 1.07 | 1.57 ± 0.87 | 1.81 ± 1.38 | 1.03 ± 0.64∗ | 1.73 ± 1.0 | 1.3 ± 0.56∗ |
| AMH ng/ml | 11.72 ± 5.8 | 10.26 ± 4.6∗∗ | 11.5 ± 5.8 | 12.6 ± 6.25 | 12.01 ± 5.6 | 10.4 ± 4.7∗ |
Comparison of the data at baseline and after treatment within the groups. ∗ p < 0.05; ∗∗ p < 0.001.